Azithromycin acts as an immunomodulatory agent to suppress the expression of TREM-1 in Bacillus pyocyaneus-induced sepsis

Immunology Letters

Volumn 138, Issue 2, 2011, Pages 137-143

  Tong, Jin ^a   Liu, Zeng Chang ^a   Wang, Dao Xin ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Azithromycin; Immunoregulation; Macrolides; TREM 1

Indexed keywords

AZITHROMYCIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING;

ANIMALS; AZITHROMYCIN; BACILLUS; BLOTTING, WESTERN; CELL LINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GRAM-POSITIVE BACTERIAL INFECTIONS; IMMUNOCONJUGATES; IMMUNOMODULATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEPSIS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959537295     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.04.001     Document Type: Article

References (38)

1. Hunter P. Sepsis under siege: a new understanding of sepsis might lead to the development of therapies to treat septic shock. EMBO Rep 2006, 7(7):667-669.
2. Bouchon A., Hernández-Munain C., Cella M., Colonna M.A. DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 2001, 194(8):1111-1122.
3. Bouchon A., Dietrich J., Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000, 164(10):4991-4995.
4. Colonna M., Facchetti F. TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. J Infect Dis 2003, 187(2):S397-401.
5. Gingras M.C., Lapillonne H., Margolin J.F. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol 2002, 38(11):817-824.
6. Bleharski J.R., Kiessler V., Buonsanti C., Sieling P.A., Stenger S., Colonna M., et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol 2003, 170(7):3812-3818.
7. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol 2003, 3(6):445-453.
8. Bouchon A., Facchetti F., Weigand M.A., Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410(6832):1103-1107.
9. Bleharski J.R., Kiessler V., Buonsanti C., Sieling P.A., Stenger S., Colonna M., et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol 2003, 170(7):3812-3818.
10. Gibot S., Kolopp-Sarda M.N., Béné M.C., Cravoisy A., Levy B., Faure G.C., et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004, 141(1):9-15.
11. Gibot S., Cravoisy A., Levy B., Bene M.C., Faure G., Bollaert P.E. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004, 350(5):451-458.
12. Gibot S., Kolopp-Sarda M.N., Béné M.C., Bollaert P.E., Lozniewski A., Mory F., et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004, 200(11):1419-1426.
13. Ianaro A., Ialenti A., Maffia P., Sautebin L., Rombolà L., Carnuccio R., et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000, 292(1):156-163.
14. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290(13):1749-1756.
15. Ivetić Tkalcević V., Bosnjak B., Hrvacić B., Burns J.L., Quittner A.L., Cibene D.A., et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 2006, 539(1-2):131-138.
16. Gibot S., Le Renard P.E., Bollaert P.E., et al. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med 2005, 31(4):594-597.
17. Netea M.G., Azam T., Ferwerda G., Girardin S.E., Kim S.H., Dinarello C.A. Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. J Leukoc Biol 2006, 80(6):1454-1461.
18. Radsak M.P., Salih H.R., Rammensee H.G., Schild H. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol 2004, 172(8):4956-4963.
19. Gibot S., Cravoisy A., Kolopp-Sarda M.N., Béné M.C., Faure G., Bollaert P.E., et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005, 33(4):792-796.
20. Liu C.L., Hsieh W.Y., Wu C.L., Kuo H.T., Lu Y.T. Triggering receptor expressed on myeloid cells-1 in pleural effusions: a marker of inflammatory disease. Respir Med 2007, 101(5):903-909.
21. Kofoed K., Andersen O., Kronborg G., Tvede M., Petersen J., Eugen-Olsen J., et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007, 11(2):R38.
22. Parnham M.J. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18(2):125-131.
23. Culić O., Eraković V., Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001, 429(1-3):209-229.
24. Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004, 54(1):21-28.
25. Tsai W.C., Standiford T.J. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm Des 2004, 10(25):3081-3093.
26. Shinkai M., Henke M.O., Rubin B.K. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008, 117(3):393-405.
27. Giamarellos-Bourboulis E.J., Adamis T., Laoutaris G., et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004, 48(1):93-99.
28. Legssyer R., Huaux F., Lebacq J., Delos M., Marbaix E., Lebecque P., et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 2006, 7:134.
29. MacLeod C.M., Hamid Q.A., Cameron L., MacLeod C.M., Hamid Q.A., Cameron L., Tremblay C., Brisco W. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther 2001, 18(2):75-82.
30. Wallwork B., Coman W., Feron F., Mackay-Sim A., Cervin A. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope 2002, 112(10):1827-1830.
31. Suzuki H., Shimomura A., Ikeda K., Oshima T., Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med 1997, 182(2):115-124.
32. Kikuchi T., Hagiwara K., Honda Y., Gomi K., Kobayashi T., Takahashi H., et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002, 49(5):745-755.
33. Desaki M., Okazaki H., Sunazuka T., Omura S., Yamamoto K., Takizawa H. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation. Antimicrob Agents Chemother 2004, 48(5):1581-1585.
34. Imamura Y., Yanagihara K., Mizuta Y., Seki M., Ohno H., Higashiyama Y., et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 cells. Antimicrob Agents Chemother 2004, 48(9):3457-3461.
35. Yamasawa H., Oshikawa K., Ohno S., Sugiyama Y. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol 2004, 30(4):569-575.
36. Ojaniemi M., Glumoff V., Harju K., Liljeroos M., Vuori K., Hallman M. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol 2003, 33(3):597-605.
37. Guillot L., Le Goffic R., Bloch S., Escriou N., Akira S., Chignard M., et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005, 280(February (7)):5571-5580.
38. Tessarz A.S., Weiler S., Zanzinger K., Angelisová P., Horejsí V., Cerwenka A. Non-T cell activation linker (NTAL) negatively regulates TREM-1/DAP12-induced inflammatory cytokine production in myeloid cells. J Immunol 2007, 178(4):1991-1999.